NEW YORK (GenomeWeb) – The National Comprehensive Cancer Network issued updated prostate cancer guidelines that include new information about the role of family history, mutations in DNA repair genes, and testing for microsatellite instability and mismatch repair status for potential treatment with the Merck drug Keytruda (pembrolizumab).

This latest update recommends that men with regional and metastatic disease should have tumor testing for homologous recombination gene mutations and have their tumors assessed for microsatellite instability or mismatch repair deficiency.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.